Anti–vascular endothelial growth factor drugs for age-related macular degeneration

Record ID 32018005333
Authors' objectives: What are the evidence-based guidelines regarding the use of anti-VEGF drugs for adult patients with suspected or confirmed wet AMD?
Authors' results and conclusions: Wet age-related macular degeneration (AMD) is a serious health concern that causes reduced vision-related function, poor overall quality of life, and increased health care resource usage. Antivascular endothelial growth factor (VEGF) drugs are the first-line treatment for wet AMD, and they are injected into the eye. These drugs can slow disease progression but are expensive and require trained medical professionals to administer and monitor treatment response. The criteria for initial injection, maintenance, and discontinuation of anti-VEGF drugs in patients with wet AMD remain unclear.
Project Status: Completed
Year Published: 2023
English language abstract: An English language summary is available
Publication Type: Rapid Review
Country: Canada
MeSH Terms
  • Macular Degeneration
  • Wet Macular Degeneration
  • Intravitreal Injections
  • Angiogenesis Inhibitors
  • Receptors, Vascular Endothelial Growth Factor
  • Bevacizumab
  • Ranibizumab
  • Vascular Endothelial Growth Factor A
  • Visual Acuity
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
Contact Email:
Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.